Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Valuation in context
No metrics available yet for AVLN.
Free · No credit card needed
Get alerted when AVLN is cheap
Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.
